Jeffrey Hubbell to Melanoma
This is a "connection" page, showing publications Jeffrey Hubbell has written about Melanoma.
Connection Strength
2.250
-
Engineered IL-7 synergizes with IL-12 immunotherapy to prevent T cell exhaustion and promote memory without exacerbating toxicity. Sci Adv. 2023 12; 9(48):eadh9879.
Score: 0.681
-
Masking the immunotoxicity of interleukin-12 by fusing it with a domain of its receptor via a tumour-protease-cleavable linker. Nat Biomed Eng. 2022 07; 6(7):819-829.
Score: 0.611
-
Recruitment of CD103+ dendritic cells via tumor-targeted chemokine delivery enhances efficacy of checkpoint inhibitor immunotherapy. Sci Adv. 2019 12; 5(12):eaay1357.
Score: 0.517
-
Membrane-localized neoantigens predict the efficacy of cancer immunotherapy. Cell Rep Med. 2023 08 15; 4(8):101145.
Score: 0.167
-
Lymphangiogenesis-inducing vaccines elicit potent and long-lasting T cell immunity against melanomas. Sci Adv. 2021 03; 7(13).
Score: 0.141
-
Collagen-binding IL-12 enhances tumour inflammation and drives the complete remission of established immunologically cold mouse tumours. Nat Biomed Eng. 2020 05; 4(5):531-543.
Score: 0.132